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Introduction
Sildenafil inhibits phosphodiesterases type 5, an enzyme
that metabolizes cGMP. It is approved for the treatment of
erectile dysfunction and pulmonary arterial hypertension.
Early clinical studies showed a beneficial effect in
endothelial dysfunction and severe systolic heart failure.
The aim of this study was to examine the efficacy and tol-
erability of chronic sildenafil on exercise capacity and
quality of life in patients with stable systolic heart failure.
Methods
In this double blind, placebo-controlled study, 31
patients were screened and 23 patients with symptomatic
but stable systolic heart failure were randomized to pla-
cebo (P) or sildenafil (S). S was given in 20 mg dose three
times daily for 6 weeks (W6) and then was increased to 40
mg tds for further 10 weeks (W16). The primary end-point
was the change in six minute walk distance (6MWT) from
baseline. The International index of erectile function
(IIEF), Beck's depression inventory (BDI) and the Minne-
sota living with heart failure questionnaire (LHFQ) were
used to assess the functional outcome.
Results
12 patients were randomized to S and 11 to P. The ejec-
tion fraction (mean ± SEM) was S = 30 ± 1.8%; P = 28 ±
2.6%, and 78% of the randomized group were in NYHA
II. The 6MWT improved from baseline in both groups but
it was not statistically significant between groups (Fig. 1).
Two of 12 patients on S and non in P were withdrawn
from the study (due to pre-existing atrial fibrillation and
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chest pain). The baseline IIEF score showed evidence of
erectile dysfunction in both groups (EF domain, S = 12.6
± 2.8 P = 10.1 ± 3.5), with significant improvement in
only the overall satisfaction domain in the S group at W16
compared to placebo (+2.5 points; P = 0.04). BDI baseline
score was normal in both group but there was significant
improvement of 3 points in favour of S at W16 (P = 0.03).
There were no significant changes in the LHFQ in both
groups.
Conclusion
Sildenafil was well tolerated in this group of patients.
There was no significant difference in the placebo cor-
rected 6MWT or LHFQ at week 16. However there was
improvement in some functional parameters of erectile
dysfunction and the Beck depression score, therefore,
larger studies are warranted.Page 2 of 2
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